Investor Forum

RNS Number : 0639T

Venture Life Group PLC

01 October 2014

 

Venture Life Group plc

("Venture Life" or "the Group")

Venture Life to present at Proactive Investors One2One Investors Forum on

Thursday 2 October 2014

Bracknell, UK - 1 October 2014: Venture Life Group plc (AIM: VLG), the international consumer products group addressing the self-care needs of the ageing population, announces that Jerry Randall, Venture Life's Chief Executive Officer, will be presenting at the Proactive Investors One2One Investors Forum tomorrow night, Thursday 2 October 2014.

The event will run from 6:00pm to 8:00pm, followed by a drinks reception.

Further information, including a link to register participation, can be found at:

http://www.proactiveinvestors.co.uk/register/event_details/249

The event is being held at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, London W1J 5EB in the Charles Suite.

The event is open to private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

- Ends -

For further information please contact:

Venture Life Group PLC

James Hunter, Chief Financial Officer                                   [phone]

Square1 Consulting

David Bick

Mark Longson                                                                         [phone]

JW Communications

Julia Wilson                                                                             [phone]

Notes to editors

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its topical development and manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 50 countries and currently include:

·     food supplements to maintain brain function and memory;

·     dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

·     medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

END

 

 

NRAQKKDBPBKDACN